From PsychonautWiki
(Redirected from 3-Me-PCP)
Jump to navigation Jump to search

This page has not been fully approved by the PsychonautWiki administrators.

It may contain incorrect information, particularly with respect to dosage, duration, subjective effects, toxicity and other risks. It may also not meet PW style and grammar standards.

Summary sheet: 3-Me-PCP
Chemical Nomenclature
Common names 3-Me-PCP
Substitutive name 3-Methoxyphencyclidine
Systematic name 1-[1-(3-methylphenyl)cyclohexyl]piperidine
Class Membership
Psychoactive class Dissociative
Chemical class Arylcyclohexylamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.

Threshold 2 mg
Light 5 - 10 mg
Common 10 - 20 mg
Strong 20 - 25 mg
Heavy 25 mg + Heavy doses may result in psychosis and mania.[1]
Total 45 - 120 minutes
Threshold 5 mg
Light 5 - 10 mg
Common 10 - 20 mg
Strong 20 - 30 mg
Heavy 30 mg + Heavy doses may result in psychosis and mania.[1]
Total 4 - 8 hours
Onset 30 - 90 minutes
Come up 45 - 120 minutes
Peak 2 - 3 hours
Offset 1 - 2 hours
After effects 4 - 48 hours

Threshold 5 mg
Light 5 - 10 mg
Common 10 - 20 mg
Strong 20 - 25 mg
Heavy 15 mg + Heavy doses may result in psychosis and mania.[1]
Total 3 - 5 hours
Onset 5 - 30 minutes
Come up 45 - 90 minutes
Peak 1.5 - 2 hours
Offset 45 - 60 minutes
After effects 4 - 48 hours

DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.


3-Methylphencyclidine (also known as 3-Me-PCP) is a lesser-known novel dissociative substance of the arylcyclohexylamine class. 3-Me-PCP is a derivative of phencyclidine (PCP) and is chemically related to substances like 3-HO-PCP and 3-MeO-PCP. It produces its effects by blocking NMDA receptors in the brain.

Like other arylcyclohexylamines, 3-Me-PCP induces a state referred to as "dissociative anesthesia", although the extent to which this occurs is reported to be highly dose-dependent and variable in its effects. It is commonly taken orally and nasally.

Very little data exists for the pharmacology, metabolism, and toxicity of 3-Me-PCP. Due to its potent hallucinogenic effects and lack of research, it is strongly advised to use use harm reduction practices if using this substance. In 2020, it began to be discussed on online forums such as & and was soon made available for sale on the research chemicals market.


3-Methylphencyclidine, or 3-Me-PCP, is a synthetic dissociative of the arylcyclohexylamine class. 3-Me-PCP contains cyclohexane, a six-member saturated ring, bonded to two additional rings at R1. One of these rings is a piperidine ring, a nitrogenous six member ring, bonded at its nitrogen group. The other ring is an aromatic phenyl ring, substituted at R3 with a methyl group.


Further information: NMDA receptor antagonist

3-Me-PCP acts as an NMDA receptor antagonist. A specific subtype of glutamate receptor, NMDA (N-Methyl-D-Aspartate), modulates the transmission of electrical signals between neurons in the brain and spinal cord; for the signals to pass, the receptor must be open.

Dissociatives inhibit the normal functioning NMDA receptors by binding to and blocking them. This disruption of neural network activity leads to loss of normal cognitive and affective processing, psychomotor functioning, anesthesia and eventually the equivalent of a "k-hole".

The closely related 3-Me-PCPy is know to be a triple reuptake inhibitor, and it is possible 3-Me-PCP shares this pharmacological action.

Subjective effects

3-Me-PCP is commonly described as being more stimulating and less immobilizing than other dissociatives such as ketamine or MXE. At lower doses, it can induce sensory enhancements such as color enhancement, acuity enhancement, tactile enhancement, auditory enhancement and bodily control enhancement. However, at medium to high doses, it presents sensory suppressions such as tactile suppression, motor control loss, auditory suppression and acuity suppression. Based on a large amount of experience reports, it appears to be considerably more likely to induce mania, delusions, and psychosis than other dissociatives (possibly due to its unusually high potency, compulsivity and erratic dose response).

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects

Visual effects

Cognitive effects

Auditory effects

Disconnective effects

Experience reports

Anecdotal reports which describe the effects of this compound within our experience index include:

Toxicity and harm potential

The toxicity and long-term health effects of recreational 3-Me-PCP use has not been studied in any scientific context and the exact toxic dosage is unknown. This is because 3-Me-PCP has very short history of human usage.

Dependence and abuse potential

3-Me-PCP produces dependence with chronic use and has a high potential for abuse. In comparison to other dissociatives, 3-Me-PCP has been reported to be more likely to produce psychological dependence than other dissociatives. When dependence has developed, cravings and withdrawal effects may occur if one suddenly stops their usage.

Tolerance to many of the effects of 3-Me-PCP develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption). 3-Me-PCP presents cross-tolerance with all dissociatives, meaning that after the consumption of 3-Me-PCP, all dissociatives will have a reduced effect.


3-Me-PCP has been reported to cause psychosis, delusions, and mania at a significantly higher rate than other dissociatives such as ketamine, diphenidine, or MXE.

  • Users should avoid taking 3-Me-PCP for multiple days in a row or becoming dependent on it as this seems to be the main risk factor in the observed incidences of severe adverse effects.
  • The recommended dosage range should not be exceeded as high doses can trigger these effects as well.
  • Users should start with extremely low doses and work their way up as slowly as possible. Volumetric liquid dosing should preferably be used due to the drug's potency; most standard milligram scales cannot accurately weigh out doses below 10-15mg.
  • Compulsive redosing before one has fully sobered up is not recommended and can result in too high of a dose.

Due to the risk of psychosis, it is not recommended to combine this substance with other substances, especially stimulants, psychedelics, or other dissociatives like MXE. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

It is strongly advised to use harm reduction practices when using this substance.

Urinary tract effects

In terms of its long-term health effects when used repeatedly and excessively for extended periods of time, 3-Me-PCP seems to exhibit almost identical bladder and urinary tract problems to those found within ketamine, but to a lesser extent. This is possibly because 3-Me-PCP is far more potent than ketamine so significantly less of drug needs to be consumed. Symptoms of ketamine-induced cystitis can become extremely serious and can be described as:

  • Urinary frequency - Urinary frequency is the need to empty the bladder every few minutes.
  • Urinary urgency - This can be described as a sudden, compelling need to urinate.
  • Urinary pressure - This is experienced as a constant sensation of fullness in the bladder that is unrelieved by urination.
  • Pelvic and bladder pain - Pain can develop suddenly and severely, particularly as the bladder fills with urine.
  • Hematuria - Hematuria is visible blood in the urine.
  • Incontinence - This is the leakage of urine.

These effects can be mitigated by refraining from using 3-Me-PCP regularly (on a daily or weekly basis) and manually limiting one's usage of the substance.

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

  • Stimulants - Both stimulants and dissociatives carry the risk of adverse psychological reactions like anxiety, mania, delusions and psychosis and these risks are exacerbated when the two substances are combined.
  • Depressants - Because both depress the respiratory system, this combination can result in an increased risk of suddenly falling unconscious, vomiting and choking to death from the resulting suffocation. If nausea or vomiting occurs, users should attempt to fall asleep in the recovery position or have a friend move them into it.

Legal status

  • United States: 3-Me-PCP is not a controlled substance in the United States but possession or distribution of 3-Me-PCP for human use could potentially be prosecuted under the Federal Analogue Act due to its structural and pharmacological similarities to PCP.
  • Germany: 3-Me-PCP is controlled under the NpSG (New Psychoactive Substances Act)[2] as of July 18, 2019.[3] Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.[4]

See also

External links

Discussion and Media


  1. 1.0 1.1 1.2 3-Me-PCP Psychosis (PsychonautWiki) |
  2. "Anlage NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019. 
  3. "Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes" (PDF). Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27 (in German). Bundesanzeiger Verlag. July 17, 2019. pp. 1083–1094. Retrieved January 1, 2020. 
  4. "§ 4 NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.